| Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study J Burisch, G Kiudelis, L Kupcinskas, HAL Kievit, KW Andersen, ... Gut 68 (3), 423-433, 2019 | 251 | 2019 |
| Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort—an Epi-IBD study J Burisch, KH Katsanos, DK Christodoulou, L Barros, F Magro, ... Journal of Crohn's and Colitis 13 (2), 198-208, 2019 | 149 | 2019 |
| Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) C Eriksson, J Marsal, D Bergemalm, L Vigren, J Björk, M Eberhardson, ... Scandinavian journal of gastroenterology 52 (6-7), 722-729, 2017 | 131 | 2017 |
| Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study A Moens, CJ van der Woude, M Julsgaard, E Humblet, J Sheridan, ... Alimentary pharmacology & therapeutics 51 (1), 129-138, 2020 | 115 | 2020 |
| Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study J Burisch, H Vardi, D Schwartz, M Friger, G Kiudelis, J Kupčinskas, ... The lancet Gastroenterology & hepatology 5 (5), 454-464, 2020 | 106 | 2020 |
| Systemic inflammation in preclinical ulcerative colitis D Bergemalm, E Andersson, J Hultdin, C Eriksson, ST Rush, R Kalla, ... Gastroenterology 161 (5), 1526-1539. e9, 2021 | 75 | 2021 |
| Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature C Eriksson, A Gustavsson, T Kronvall, C Tysk J Gastrointestin Liver Dis 20 (1), 77-80, 2011 | 74 | 2011 |
| Changes in medical management and colectomy rates: a population‐based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963‐2010 C Eriksson, Y Cao, S Rundquist, Y Zhulina, I Henriksson, S Montgomery, ... Alimentary pharmacology & therapeutics 46 (8), 748-757, 2017 | 72 | 2017 |
| Genomic characterization and outcome of prosthetic joint infections caused by Staphylococcus aureus P Wildeman, S Tevell, C Eriksson, AC Lagos, B Söderquist, B Stenmark Scientific reports 10 (1), 5938, 2020 | 50 | 2020 |
| The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register S Shrestha, O Olén, C Eriksson, ÅH Everhov, P Myrelid, I Visuri, ... Scandinavian Journal of Gastroenterology 55 (4), 430-435, 2020 | 45 | 2020 |
| Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study C Eriksson, I Henriksson, O Brus, Y Zhulina, N Nyhlin, C Tysk, ... Alimentary pharmacology & therapeutics 48 (6), 638-645, 2018 | 43 | 2018 |
| Endoscopic postoperative recurrence in Crohn’s disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: a real-world … H Yanai, A Kagramanova, O Knyazev, J Sabino, S Haenen, GJ Mantzaris, ... Journal of Crohn's and Colitis 16 (12), 1882-1892, 2022 | 33 | 2022 |
| Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register J Thunberg, O Björkqvist, CRH Hedin, A Forss, C Söderman, ... United European Gastroenterology Journal 10 (7), 631-639, 2022 | 31 | 2022 |
| Disease course of inflammatory bowel disease unclassified in a European population‐based inception cohort: An Epi‐IBD study J Burisch, SC Zammit, P Ellul, S Turcan, D Duricova, M Bortlik, ... Journal of gastroenterology and hepatology 34 (6), 996-1003, 2019 | 29 | 2019 |
| Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study C Eriksson, S Rundquist, Y Cao, S Montgomery, J Halfvarson Gut 68 (4), 623-632, 2019 | 29 | 2019 |
| Epi-IBD group J Burisch, H Vardi, D Schwartz, M Friger, G Kiudelis, J Kupčinskas, ... Health-care costs of inflammatory bowel disease in a pan-European, community …, 2018 | 28 | 2018 |
| Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers S Rundquist, MC Sachs, C Eriksson, O Olén, S Montgomery, J Halfvarson, ... Alimentary Pharmacology & Therapeutics 53 (4), 471-483, 2021 | 26 | 2021 |
| Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study C Eriksson, S Rundquist, V Lykiardopoulos, R Udumyan, P Karlén, O Grip, ... Therapeutic advances in gastroenterology 14, 17562848211023386, 2021 | 21 | 2021 |
| I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease L Peyrin-Biroulet, JF Rahier, J Kirchgesner, V Abitbol, S Shaji, A Armuzzi, ... Clinical Gastroenterology and Hepatology 21 (3), 771-788. e10, 2023 | 20 | 2023 |
| Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) S Rundquist, C Eriksson, L Nilsson, L Angelison, S Jäghult, J Björk, ... Scandinavian journal of gastroenterology 53 (10-11), 1257-1263, 2018 | 16 | 2018 |
